Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen

References

• Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567–572. doi:10.1182/blood.V72.2.567.bloodjournal722567
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021–1028. doi:10.1056/NEJM199710093371501
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American intergroup protocol. Blood. 2002;100(13):4298–4302. doi:10.1182/blood-2002–02–0632
   PubMed Web of Science ®Google Scholar
• Shen Z-X, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354–3360. doi:10.1182/blood.V89.9.3354
   PubMed Web of Science ®Google Scholar
• Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 group. Blood. 1993;82(11):3241–3249. doi:10.1182/blood.V82.11.3241.bloodjournal82113241
   PubMed Web of Science ®Google Scholar
• Tallman MS, Nabhan C, Feusner JH, et al. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99(3):759–767. doi:10.1182/blood.v99.3.759
   PubMed Web of Science ®Google Scholar
• Adès L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the european APL group experience. Blood. 2010;115(9):1690–1696. doi:10.1182/blood-2009–07–233387
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group. Blood. 2010;116(17):3171–3179. doi:10.1182/blood-2010–03–276196
   PubMed Web of Science ®Google Scholar
• Sanz M, Martin G, Gonzalez M, et al. Risk adapted treatment of acute promyelocytic leukaemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103(4):1237–1243. doi:10.1182/blood-2003–07–2462
   PubMed Web of Science ®Google Scholar
• Shen Z-X, Shi Z-Z, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101(15):5328–5335. doi:10.1073/pnas.0400053101
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121. doi:10.1056/NEJMoa1300874
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305. doi:10.1016/S1470-2045(15)00193-X
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in Non-High-Risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605–612. doi:10.1200/JCO.2016.67.1982
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Bixby D, Perl A, et al. NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16–27. doi:10.6004/jnccn.2021.0002
   PubMed Web of Science ®Google Scholar
• Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the european LeukemiaNet. Blood. 2019;133(15):1630–1643. doi:10.1182/blood-2019-01-894980
   PubMed Web of Science ®Google Scholar
• Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the european LeukemiaNet MRD working party. Blood. 2021;138(26):2753–2767. doi:10.1182/blood.2021013626
   PubMed Web of Science ®Google Scholar
• Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the australasian leukaemia and lymphoma group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015;2(9):e357–e366. doi:10.1016/S2352-3026(15)00115-5
   PubMed Web of Science ®Google Scholar
• Hu J, Liu Y-F, Wu C-F, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106(9):3342–3347. doi:10.1073/pnas.0813280106
   PubMed Web of Science ®Google Scholar
• Miller KP, Venkataraman G, Gocke CD, et al. Bone marrow findings in patients with acute promyelocytic leukemia treated with arsenic trioxide. Am J Clin Pathol. 2019;152(5):675–685. doi:10.1093/ajcp/aqz087
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Acute myeloid leukemia (Version 2). 2022. https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
   Google Scholar
• Cicconi L, Divona M, Ciardi C, et al. PML-RARakinetics and impact of FLT3-ITDmutations in newly diagnosed acute promyelocytic leukaemiatreated with ATRA and ATO or ATRA and chemotherapy. Leukemia. 2016;30(10):1987–1992. doi:10.1038/leu.2016.122
   PubMed Web of Science ®Google Scholar
• Stone RM, Maguire M, Goldberg MA, et al. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood. 1988;71(3):690–696. doi:10.1182/blood.V71.3.690.690
   PubMed Web of Science ®Google Scholar
• Virk H, Khaire N, Sreedharanunni S, et al. Significance of dysplastic neutrophils with multiple auer rods in post-therapy acute promyelocytic leukemia. Indian J Hematol Blood Transfus. 2022;38(1):199–201. doi:10.1007/s12288-021-01493-y
   PubMed Web of Science ®Google Scholar
• Dalal BI, Bruyere H, Barnett MJ. Significance of persistent auer rods and cytogenetic abnormality after first cycle of therapy for acute promyelocytic leukaemia. Br J Haematol. 2007;137(5):385–385. doi:10.1111/j.1365-2141.2007.06541.x
   PubMedGoogle Scholar